Biocon Biologics  /  Commitment


Biocon Biologics has built its business culture on a bedrock of purpose, ethics and equity. A purpose-driven business philosophy has provided us with a compelling reason to embed social impact in all that we do. From our origins as a pioneering biotechnology enterprise that inculcated a research-driven strategy to address eco-friendly, enzyme-based solutions in industrial processing to our innovation-led healthcare solutions that provide affordable access to patients who battle cancer, diabetes and autoimmune diseases, we are propelled with a sense of business responsibility that has both ethics and equity at its core.

Industry Mover

Biocon is the only company from the global biotech industry to be recognized as “Industry Mover” in the S&P Global Sustainability Yearbook 2023.

More >>

A step up on the ESG index

Biocon scored 52 in the Dow Jones Sustainability Index for 2022, up from its 2021 score of 45, showing improvement in all three dimensions — environmental, governance and social.

More >>

Strategic Action. Transformational Growth.

Transformation is the central theme of our growth story. It defines the strategies we adopt and the actions we take.

While we develop cutting-edge therapies to transform healthcare, we also care about the health of our planet and the welfare of our people and the communities in which we operate. Our responsible business practices, which embed social impact in all that we do, includes adopting strong Environmental, Social and Governance (ESG) practices.

Know More
Patient Equity

Over the years, we have built a strong, affordable innovation model, which has enabled us to lower the cost of lifesaving therapies and bring them within the reach of people suffering from chronic diseases like diabetes, cancer and autoimmune conditions. Affordability has always been a challenge to patients in low- and middle-income countries (LMICs), as well as, to those that cannot afford insurance in many high-income countries. Our biosimilars for cancer such as Trastuzumab and Bevacizumab, as well as our human insulin and insulin analogs for people with diabetes are providing equitable and affordable access to millions of patients across the world.

People Equity

Underpinning our patient equity initiatives is our commitment to create a collaborative, empowering, diverse, equitable and inclusive workplace. We aim to make Biocon an equal opportunity enterprise, from recruitment to career and leadership development. We would like to get to a 50:50 gender ratio by 2030 as we firmly believe that greater gender diversity offers benefits such as corporate governance, leadership, entrepreneurship and innovation.

Environmental Equity

While we pursue our purpose of using biotechnology to develop therapies that heal the world, we are equally concerned about the health of our planet and the depleting ecological balance. As a responsible corporate citizen, we have designed our operations to enable environmental sustainability with a low carbon footprint, maximum recycling of wastewater and use of green power.

Biocon ESG Report 2022
Transform Action

Biocon’s problem-solving spirit has led it to harness the transformational power of biotechnology-led innovation to improve the health and well-being of humanity. Over the past four decades, we have leveraged our knowledge of modern molecular biotechnology to engineer organisms with beneficial traits, thus enabling new solutions to the challenges of disease.

Know More
Stakeholder Equity

At Biocon Biologics, the principles of integrity, transparency, accountability and ethics resonate throughout the organization and reinforce the equity we enjoy with our various stakeholders. We have established globally benchmarked standards of governance to build an environment of trust necessary for fostering long-term investment, financial stability and business integrity, thereby supporting stronger growth and more inclusive societies.

Social Equity

At Biocon Biologics, we believe that investing in the growth of people is the best kind of investment. Biocon Foundation is integral to our commitment to improving people’s lives. The Foundation is the principal channel for our corporate philanthropy to build resilient solutions that enable underserved communities to live better, every day. We envision a future where everyone prospers in a secure environment with equal access to healthcare, education and sustainable livelihoods.

Enabling Equitable Access to Affordable Healthcare

Biocon has had a rich legacy of challenging the status quo and breaking barriers, and this is what led it to foray into biosimilars more than 20 years ago. Everything that we do at Biocon Biologics today has just one purpose – transforming lives by enabling equitable access to life-saving affordable biosimilars impacting billions of lives globally.

buy twitter followers